Recruiting
Phase 2

TP-06

Sponsor:

Tarsus Pharmaceuticals, Inc.

Code:

NCT07886268

Conditions

Persistent Corneal Epithelial Defect

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

TP-06

Vehicle of TP-06

Study Details

Brief summary:

Capellion is a Phase 2 trial comparing TP-06 2.0% with Vehicle in up to 32 adults with persistent corneal epithelial defects. Participants will receive treatment for 8 weeks and be followed for 2 additional weeks to assess corneal healing and safety.

Conditions

Persistent Corneal Epithelial Defect

Study ID

NCT07886268

Start date

Apr 20, 2026

Status verified date

Oct, 2026

Completion date

Jul 7, 2028

Anticipated

Primary completion date

Jul 7, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Able and willing to provide written informed consent
  • Presence of a non-infected persistent corneal epithelial defect (PCED) in one eye that has failed to heal after at least 10 days of appropriate standard-of-care treatment
  • Stable lesion size between Screening and Baseline as assessed by the Investigator

Exclusion Criteria:

  • Active ocular infection in either eye
  • Corneal perforation or high risk of corneal perforation
  • Severe eyelid abnormalities
  • Ocular or eyelid surgery in the study eye within 3 months prior to Baseline (unless PCED was caused by surgery)
  • Use of prohibited ophthalmic medications or procedures as defined in the protocol
  • Any condition that, in the Investigator's judgment, would interfere with study participation or interpretation of results

Note: Additional exclusion criteria apply, as defined in the protocol

Study Design

Enrollment

32 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: TP-06 Ophthalmic Solution

placebo comparator: Vehicle of TP-06 Ophthalmic Solution

Interventions

TP-06

TP-06 ophthalmic solution

Vehicle of TP-06

Vehicle of TP-06 ophthalmic solution

Primary outcome measure

  • Proportion of participants achieving complete resolution of corneal fluorescein staining (CFS) in the study eye at day 56, maintained through day 70. [ Time Frame: Day 56 and Day 70 ]

Central Contacts and Locations

Central contacts

Study Director

888-421-4002clinical@tarsusrx.com

Study Coordinator

888-421-4002

Locations

Tarsus Investigative Site

Recruiting

Atlanta, Georgia, United States, 30339

Tarsus Investigative Site

Recruiting

Alexandria, Minnesota, United States, 56308

Tarsus Investigative Site

Recruiting

Houston, Texas, United States, 77008

Tarsus Investigative Site

Recruiting

Sugar Land, Texas, United States, 77478

More Information

Sponsor

Tarsus Pharmaceuticals, Inc.

Last update posted

Oct 21, 2026

Last verified

Oct, 2026

Keywords

  • persistent corneal epithelial defect
  • PCED
  • corneal healing
  • vehicle-controlled

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-22. This information was provided to ClinicalTrials.gov by Tarsus Pharmaceuticals, Inc. on 2026-10-21. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.